Systemic Treatment of Cervical Cancer

A rare type of cervical cancer was encountered as a neuroendocrine cancer of cervix. Clinically, the patient presented with bleeding per vagina. She refused biopsy in her first visit and did not come for follow up. However, after few months she came and since there was a polypoid growth from cervix, she was advised to undergo hysterectomy. Histopathologically, it was diagnosed as large cell type of neuroendocrine cancer. Multimodality systemic treatment was offered as per literature. Ibrahim Med. Coll. J. 2009; 3(1): 36-38 Key words: Uterine cervix, neuroendocrine cancer (NEC), human papilloma virus (HPV) doi: 10.3329/imcj.v3i1.2919

Download Full-text

Treatment patterns in cervical cancer patients initiating systemic therapy.

Journal of Clinical Oncology ◽

10.1200/jco.2020.38.15_suppl.e18009 ◽

2020 ◽

Vol 38 (15_suppl) ◽

pp. e18009-e18009

Author(s):

Anuj Shah ◽

Nehemiah Kebede ◽

Ruchit Shah ◽

Shelby Corman ◽

Chizoba Nwankwo

Keyword(s):

Cervical Cancer ◽

Cancer Patients ◽

Systemic Therapy ◽

Systemic Treatment ◽

Descriptive Analysis ◽

Previous Treatment ◽

Baseline Period ◽

Treatment Patterns ◽

Therapy Initiation ◽

The Mean

e18009 Background: NCCN recommends the use of systemic treatment for advanced cervical cancer patients. However, no study has assessed treatment patterns in this population. This study described real-world treatments patterns among women with cervical cancer newly initiating a systemic therapy. Methods: Cervical cancer patients with ≥2 claims for systemic therapy (i.e., chemo- or immunotherapy) within a 4-week period between June 2014 – October 2018, no claims within 6 months prior to systemic treatment initiation (baseline period), and continuously enrolled within the baseline period and 3 months post therapy initiation were identified from the Optum Clinformatics DataMart database. Patients who had a cervical cancer-related surgery within ±3 months of therapy initiation were excluded to exclude adjuvant use. All claims for the same systemic therapy without a > 90-day gap or new systemic therapy started within 28 days of a previous treatment were considered to be part of the same LOT. Descriptive analysis, stratified for presence of non-cervical cancers during the baseline period, were conducted to identify most common treatments, durations, and use of mono versus combination therapy within each LOT. Results: 1,229 women newly initiated systemic therapy, 357 (29.0%) received LOT2 and 141 (11.5%) had a LOT3. Treatments received within each LOT are described in the table below. The proportion receiving radiation reduced from LOT1 (49.9%) to LOT2 (12.0%). The mean duration of LOT1 and LOT2 were 2.9 and 3.7 months. The proportion of patients receiving monotherapy in LOT1 and LOT2 were 77.8% and 64.1% respectively. Conclusions: The treatment received by patients in this analysis suggested receipt of guideline concordant care. [Table: see text]

Download Full-text

2767 Second line systemic treatment options for recurrent/advanced cervical cancer - The Royal Marsden experience

European Journal of Cancer ◽

10.1016/s0959-8049(16)31533-7 ◽

2015 ◽

Vol 51 ◽

pp. S553

Author(s):

S. Boussios ◽

D. Glaessgen ◽

A. Okines ◽

S. Lalondrelle ◽

A. Taylor ◽

...

Keyword(s):

Cervical Cancer ◽

Systemic Treatment ◽

Treatment Options ◽

Advanced Cervical Cancer ◽

Second Line

Download Full-text

Targeting the PD-1 Axis with Pembrolizumab for Recurrent or Metastatic Cancer of the Uterine Cervix: A Brief Update

International Journal of Molecular Sciences ◽

10.3390/ijms22041807 ◽

2021 ◽

Vol 22 (4) ◽

pp. 1807

Author(s):

Yannick Verhoeven ◽

Delphine Quatannens ◽

Xuan Bich Trinh ◽

An Wouters ◽

Evelien L.J. Smits ◽

...

Keyword(s):

Cervical Cancer ◽

Systemic Treatment ◽

Advanced Disease ◽

Metastatic Cancer ◽

Public Health Problem ◽

Treatment Modalities ◽

Promising Strategy ◽

Current Therapies ◽

Clinical Potential ◽

Great Public Health

Even though cervical cancer is partly preventable, it still poses a great public health problem throughout the world. Current therapies have vastly improved the clinical outcomes of cervical cancer patients, but progress in new systemic treatment modalities has been slow in the last years. Especially for patients with advanced disease this is discouraging, as their prognosis remains very poor. The pathogen-induced nature, the considerable mutational load, the involvement of genes regulating the immune response, and the high grade of immune infiltration, suggest that immunotherapy might be a promising strategy to treat cervical cancer. In this literature review, we focus on the use of PD-1 blocking therapy in cervical cancer, pembrolizumab in particular, as it is the only approved immunotherapy for this disease. We discuss why it has great clinical potential, how it opens doors for personalized treatment in cervical cancer, and which trials are aiming to expand its clinical use.

Download Full-text

A combined ultrastructural and gene molecular research for the relationship between human uterine cervical carcinoma and human papillomavirus

Proceedings, annual meeting, Electron Microscopy Society of America ◽

10.1017/s042482010015856x ◽

1990 ◽

Vol 48 (3) ◽

pp. 204-205

Author(s):

Kun Lee ◽

Jingyi Si ◽

Ricai Han ◽

Wei Zhang ◽

Bingbing Tan ◽

...

Keyword(s):

Cervical Cancer ◽

Human Papillomavirus ◽

Intraepithelial Neoplasia ◽

Hpv Infection ◽

Dot Blot ◽

Homologous Sequences ◽

Normal Cervical Epithelium ◽

The Relationship ◽

Chronic Cervicitis

There are more supports for the view that human papillomavirus (HPV) infection might be an etiological factor in the development of cervical cancer when the association of persistent condylomata is considered. Biopsies from 318 cases with squamous cell carcinoma of uterine cervix, 48 with cervical and vulvar condylomata, 14 with cervical intraepithelial neoplasia (CIN), 34 with chronic cervicitis and 24 normal cervical epithelium were collected from 5 geographic regions of China with different cervical cancer mortalities. All specimens were prepared for Dot blot, Southern blot and in situ DNA-DNA hybridizations by using HPV-11, 16, 18 DNA labelled with 32P and 3H as probes to detect viral homologous sequences in samples. Among them, 32 cases with cervical cancer, 27 with condyloma and 10 normal cervical epitheliums were randomly chosen for comparative EM observation. The results showed that: 1), 192 out of 318 (60.4%) cases of cervical cancer were positive for HPV-16 DNA probe (Table I)

Download Full-text